Clinical and biological factors predictive of malignancy in dermatomyositis

Prohić, Asja; Kasumagić-Halilovic, Emina; Šimić, Dubravka; Selmanagić, Aida

doi:10.1111/j.1468-3083.2009.03148.x

Cited by 6 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of a total of 1100 articles identified in the databases, 1055 did not meet the study criteria and were excluded from the meta‐analysis. Of the remaining 45 studies, 20 met the selection criteria, and the remaining 25 were excluded due to not being original research, being case reports, or having inadequate study design.…”

Section: Resultsmentioning

confidence: 99%

“…Most patients with CAM had DM. The studies analysed the following characteristics: age (mean ± SD; n = 13), sex ratio ( n = 18), cutaneous necrosis ( n = 10), dysphagia ( n = 12), arthritis ( n = 7), ILD ( n = 10), Gottron sign ( n = 8) and ANA ( n = 9) . The quality scores ranged from 5 to 8: 14 were high quality, six moderate quality and none low quality (Table ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of the association of dermatomyositis and polymyositis with cancer

et al. 2013

View full text Add to dashboard Cite

SummaryBackground Although some features of dermatomyositis (DM) and polymyositis (PM) have been reported as possible prognostic indicators for cancer development, previous studies were small in size and were unable to establish a definitive relationship between neoplasms and DM and PM. Objectives To evaluate risk factors for developing malignancies in patients with DM and PM. Methods Meta-analysis of the studies reported in the literature was performed to unveil risk factors for developing cancer among patients with DM and PM. The included studies were either cohort or retrospective case-control studies with information on cancer status. Risk for malignancy was determined as the odds ratio (OR) or weighted mean difference (WMD) with a 95% confidence interval (CI), determined by fixed and random effects models. Stata 10.0 software was used to identify possible publication bias. Results Twenty studies with 380 patients and 1575 controls were included in the analysis. The factors that may increase the risk of cancer in patients with DM and PM were older age (WMD 11Á41, 95% CI 9Á84-12Á98), male sex (OR 1Á92, 95% CI 1Á49-2Á48), cutaneous necrosis (OR 5Á52, 95% CI 3Á49-8Á74) and dysphagia (OR 2Á41, 95% CI 1Á50-3Á86), whereas those that may provide protection against cancer included arthritis (OR 0Á38, 95% CI 0Á24-0Á61) and interstitial lung disease (OR 0Á32, 95% CI 0Á20-0Á51). Conclusions Our data suggest that age, sex, cutaneous necrosis, dysphagia, arthritis and lung complications may influence susceptibility to cancer in patients with DM and PM.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Meta-analysis of the association of dermatomyositis and polymyositis with cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…As inflammatory myositis is not commonly associated with elevated inflammatory markers, elevation of these could signify the presence of a separate process, with malignancy being one possibility. Indeed, DM patients with an ESR above 35 mm/h are at increased risk of cancer [35,36]. Resistance to therapy [27,34,42,43] and especially persistence of skin rash also suggest the possibility of an underlying malignancy.…”

Section: Risk Factors For Malignancy In Patients With Iimmentioning

confidence: 99%

“…While skin [48] ulcerations have been reported as a risk factor [27,34], skin necrosis has the strongest association [33,[35][36][37]; these patients are twice as likely to be diagnosed with malignancy. Cutaneous vasculitis [38,39] was only assessed in two studies conducted 30 years apart and found to have a positive correlation with malignancy.…”

Section: Risk Factors For Malignancy In Patients With Iimmentioning

confidence: 99%

Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review

Tiniakou

Mammen

2015

Clinic Rev Allerg Immunol

115

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases (collectively known as myositis) affecting the skeletal muscles as well as other organ systems such as skin, lungs, and joints. The primary forms of myositis include polymyositis (PM), dermatomyositis (PM), and immune-mediated necrotizing myopathy (IMNM). Patients with these diseases experience progressive proximal muscle weakness, have characteristic muscle biopsy findings, and produce autoantibodies that are associated with unique clinical features. One distinguishing feature of these patients is that they are also known to have an increased risk of cancer. Since the first description of the association in 1916, it has been extensively reported in the medical literature. However, there have been significant variations between the different studies with regard to the degree of cancer risk in patients with IIM. These discrepancies can, in part, be attributed to differences in the definition of malignancy-associated myositis used in different studies. In recent years, significant advances have been made in defining specific features of IIM that are associated with the development of malignancy. One of these has been myositis-specific antibodies (MSAs), which are linked to distinct clinical phenotypes and categorize patients into groups with more homogeneous features. Indeed, patients with certain MSAs seem to be at particularly increased risk of malignancy. This review attempts a systematic evaluation of research regarding the association between malignancy and myositis.

show abstract

“…Autoimmune necrotizing myopathy, dermatomyositis, and polymyositis have all been associated with malignancies [26,27]. Risk of malignancy is highest in the year prior to and following diagnosis [28][29][30][31][32][33][34], and it is associated with older age [33,35,36], male sex [37], cutaneous necrosis [37,38], rapid onset of disease [38], high inflammatory markers [38,39], and resistance to treatment [29]. In dermatomyositis, the presence of NXP-2 and TIF-1γ antibodies are also associated with an increased risk of malignancy [40].…”

Section: Introductionmentioning

confidence: 99%